Franklin Genomic Advancements ETF (BATS:HELX) Short Interest Update

Franklin Genomic Advancements ETF (BATS:HELX) saw a significant drop in short interest in July. As of July 31st, there was short interest totaling 2,561 shares, a drop of 37.8% from the July 15th total of 4,118 shares. Approximately 0.6% of the company’s shares are short sold. Based on an average trading volume of 4,032 shares, the short-interest ratio is currently 0.6 days.

Hedge Funds Weigh In On Franklin Genomic Advancements ETF

Several hedge funds have recently added to or reduced their stakes in the company. LPL Financial LLC lifted its stake in Franklin Genomic Advancements ETF by 22.4% in the fourth quarter. LPL Financial LLC now owns 11,133 shares of the company’s stock worth $404,000 after purchasing an additional 2,037 shares during the last quarter. Osaic Holdings Inc. boosted its position in shares of Franklin Genomic Advancements ETF by 19.1% during the second quarter. Osaic Holdings Inc. now owns 3,132 shares of the company’s stock valued at $87,000 after buying an additional 502 shares during the period. Raymond James Financial Inc. bought a new position in shares of Franklin Genomic Advancements ETF during the second quarter valued at approximately $42,000. Finally, Kestra Advisory Services LLC bought a new position in shares of Franklin Genomic Advancements ETF during the fourth quarter valued at approximately $39,000.

Franklin Genomic Advancements ETF Stock Down 0.4%

HELX stock opened at $40.99 on Wednesday. Franklin Genomic Advancements ETF has a twelve month low of $29.26 and a twelve month high of $41.76. The stock has a market capitalization of $16.40 million, a price-to-earnings ratio of 26.71 and a beta of 1.05. The firm’s fifty day simple moving average is $39.13 and its two-hundred day simple moving average is $35.76.

About Franklin Genomic Advancements ETF

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that is based on the Solactive Genomics index. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is managed by Franklin Templeton.